Abstract: The present invention relates to a film coated tablet formulation comprising tofacitinib or pharmaceutically acceptable salts thereof wherein tofacitinib or pharmaceutically acceptable salts thereof has a d (0.5) particle size less than 20 ?m. Further, the present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process.

Abstract: The present invention relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof. Furthermore the present invention also relates to stable oral topical aqueous pharmaceutical compositions comprising flurbiprofen or pharmaceutically acceptable salts thereof and dexpanthenol or pharmaceutically acceptable salts thereof and chlorhexidine or pharmaceutically acceptable salts thereof. More particularly, the present invention relates to stable oral topical aqueous pharmaceutical compositions of these combinations having desired levels of solubility, enhanced taste and absorption from mucosal surface, wherein the pH of the solution is between 6 and 7.

Abstract: The present invention relates to a pharmaceutical composition comprising flurbiprofen and tramadol or pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable excipient.

Abstract: The present invention relates to a pharmaceutical formulation comprising an immediate release phase comprising an effective amount of flurbiprofen and a controlled release phase comprising an effective amount of tramadol and pharmaceutically acceptable excipients.

Abstract: The present invention relates to an orally-disintegrating pharmaceutical formulation, which is characterized by comprising flurbiprofen and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.

Abstract: The present invention relates to a topical pharmaceutical composition of thiocolchicoside and methylsulfonylmethane comprising at least one penetration enhancer and one or more gelling agent. Furthermore, the invention relates to process for preparing the said topical pharmaceutical composition and its use for the treatment of pain and inflammatory symptoms associated with muscle-skeletal system and osteoarthritis.

Abstract: A controlled-release oral solution formulation, which gels in the stomach, includes pregabalin or a pharmaceutically acceptable salt of pregabalin and a gelling agent.

Abstract: An orally-administrable controlled-release formulation, including pregabalin or a pharmaceutically acceptable salt of pregabalin and polycarbophil, as a controlled-release agent.

Abstract: A controlled-release tablet formulation which gels in the stomach, including pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture thereof as a controlled-release agent.

Abstract: A multilayered solid oral pharmaceutical formulation of trimetazidine or a pharmaceutically acceptable salt or polymorph of trimetazidine wherein one layer of said formulation provides controlled release, while the other layer provides immediate release.